论文部分内容阅读
目的探讨蛋白酶体抑制剂MG132对He La细胞增殖的影响。方法用不同浓度的蛋白酶体抑制剂MG132(1、3、5、8和10μmol/L)处理He La细胞,MTT法检测细胞存活情况,绘制细胞生长曲线,观察MG132对细胞增殖的影响。结果 MG132浓度为1μmol/L时,对He La细胞无抑制作用(P>0.05);MG132浓度≥3μmol/L时,随着MG132浓度的增加,对He La细胞增殖的抑制作用逐渐增强(P<0.05),且呈剂量依赖性,但当MG132浓度≥8μmol/L时,对细胞的抑制作用不再增强。结论 MG132对He La细胞增殖具有抑制作用,本实验为研发基于泛素-蛋白酶体途径(ubiquitin proteasome pathway,UPP)治疗宫颈癌的新药提供了实验依据。
Objective To investigate the effect of proteasome inhibitor MG132 on the proliferation of HeLa cells. Methods HeLa cells were treated with different concentrations of proteasome inhibitor MG132 (1, 3, 5, 8 and 10 μmol / L). Cell viability was measured by MTT assay and the cell growth curve was drawn to observe the effect of MG132 on cell proliferation. Results When MG132 concentration was 1μmol / L, the proliferation of HeLa cells was not inhibited (P> 0.05). When the concentration of MG132 was ≥3μmol / L, the proliferation of HeLa cells was enhanced with the increase of MG132 concentration (P < 0.05), and in a dose-dependent manner, when the concentration of MG132≥8μmol / L, the inhibitory effect on cells was no longer enhanced. Conclusion MG132 has an inhibitory effect on the proliferation of HeLa cells. This experiment provides an experimental basis for the development of new drugs based on ubiquitin proteasome pathway (UPP) for cervical cancer.